Objective To provide evidence‐based recommendations and expert guidance for the
management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including …

Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created
recommendations for the management of antineutrophil cytoplasm antibody (ANCA) …

Objective To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain
remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) …

Objectives: We undertook a systematic literature review as a background to the European
League Against Rheumatism (EULAR) recommendations for conducting clinical trials in anti …

Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …

Abstract Objective: The Japan Research Committee for Intractable Vasculitis has fully
revised the clinical practice guidelines (CPG) for the management of antineutrophil …

Objective. The Canadian Vasculitis research network (CanVasc) is composed of physicians
from different medical specialties and researchers with expertise in vasculitis. One of its aims …

ContextImmunosuppressive therapies for antineutrophil cytoplasmic antibody (ANCA)–
associated vasculitis have greatly advanced patient survival but have turned ANCA …

Background Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV)
encompasses three disease phenotypes: granulomatosis with polyangiitis (GPA) …

Background Granulomatosis with polyangiitis (Wegener's)(GPA) and microscopic
polyangiitis (MPA) are subgroups of anti-neutrophil cytoplasmic antibody (ANCA) …